RU2018140960A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018140960A3 RU2018140960A3 RU2018140960A RU2018140960A RU2018140960A3 RU 2018140960 A3 RU2018140960 A3 RU 2018140960A3 RU 2018140960 A RU2018140960 A RU 2018140960A RU 2018140960 A RU2018140960 A RU 2018140960A RU 2018140960 A3 RU2018140960 A3 RU 2018140960A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662327214P | 2016-04-25 | 2016-04-25 | |
| US62/327,214 | 2016-04-25 | ||
| PCT/US2017/029143 WO2017189433A1 (en) | 2016-04-25 | 2017-04-24 | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018140960A RU2018140960A (ru) | 2020-05-26 |
| RU2018140960A3 true RU2018140960A3 (ru) | 2020-08-03 |
Family
ID=60089975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018140960A RU2018140960A (ru) | 2016-04-25 | 2017-04-24 | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10421811B2 (ru) |
| EP (1) | EP3448428A4 (ru) |
| JP (1) | JP2019514889A (ru) |
| KR (1) | KR20180135475A (ru) |
| CN (1) | CN109069631A (ru) |
| AR (1) | AR108317A1 (ru) |
| AU (1) | AU2017257505B2 (ru) |
| BR (1) | BR112018071287A2 (ru) |
| CA (1) | CA3020893A1 (ru) |
| CL (1) | CL2018002998A1 (ru) |
| CO (1) | CO2018011195A2 (ru) |
| IL (1) | IL262344A (ru) |
| MA (1) | MA44783A (ru) |
| MX (1) | MX2018012651A (ru) |
| RU (1) | RU2018140960A (ru) |
| SG (1) | SG11201807474SA (ru) |
| TW (1) | TW201740976A (ru) |
| WO (1) | WO2017189433A1 (ru) |
| ZA (1) | ZA201807888B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564592A (en) * | 2005-07-01 | 2011-11-25 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| AU2014320343B2 (en) | 2013-09-11 | 2020-05-28 | Medimmune Limited | Anti-B7-H1 antibodies for treating tumors |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| KR20220162844A (ko) * | 2014-05-13 | 2022-12-08 | 메디뮨 리미티드 | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 |
| EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
| MX389663B (es) | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| PH12018502623B1 (en) | 2016-06-13 | 2023-10-18 | I Mab Biopharma Co Ltd | Anti-pd-l1 antibodies and uses thereof |
| EA201991870A1 (ru) * | 2017-02-16 | 2020-02-12 | МЕДИММЬЮН, ЭлЭлСи | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| CA3064331A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3784279A1 (en) * | 2018-04-25 | 2021-03-03 | MedImmune Limited | Formulations of human anti-pd-l1 antibodies |
| CN112041348B (zh) | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
| CA3203441A1 (en) * | 2020-12-30 | 2022-07-07 | Jing Zhu | Formulations of anti-cd73 antibodies |
| CN120202024A (zh) * | 2022-11-04 | 2025-06-24 | 阿斯利康(瑞典)有限公司 | 抗ctla抗体组合物和相关方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006220828A1 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-MAdCAM antibody compositions |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| TW202442680A (zh) * | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| HRP20171653T1 (hr) * | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| CA2789061A1 (en) * | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
| US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| KR20220162844A (ko) * | 2014-05-13 | 2022-12-08 | 메디뮨 리미티드 | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| CA2965034C (en) * | 2014-10-24 | 2023-05-02 | Astrazeneca Ab | Combination of an immunomodulatory agent and an antisense oligonucleotide |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
-
2017
- 2017-04-24 EP EP17790189.9A patent/EP3448428A4/en not_active Withdrawn
- 2017-04-24 KR KR1020187033315A patent/KR20180135475A/ko not_active Ceased
- 2017-04-24 BR BR112018071287-6A patent/BR112018071287A2/pt not_active IP Right Cessation
- 2017-04-24 JP JP2018555566A patent/JP2019514889A/ja active Pending
- 2017-04-24 US US15/495,388 patent/US10421811B2/en not_active Expired - Fee Related
- 2017-04-24 MX MX2018012651A patent/MX2018012651A/es unknown
- 2017-04-24 CN CN201780023036.3A patent/CN109069631A/zh active Pending
- 2017-04-24 RU RU2018140960A patent/RU2018140960A/ru not_active Application Discontinuation
- 2017-04-24 MA MA044783A patent/MA44783A/fr unknown
- 2017-04-24 AU AU2017257505A patent/AU2017257505B2/en not_active Ceased
- 2017-04-24 WO PCT/US2017/029143 patent/WO2017189433A1/en not_active Ceased
- 2017-04-24 SG SG11201807474SA patent/SG11201807474SA/en unknown
- 2017-04-24 CA CA3020893A patent/CA3020893A1/en not_active Abandoned
- 2017-04-25 TW TW106113795A patent/TW201740976A/zh unknown
- 2017-04-25 AR ARP170101046A patent/AR108317A1/es unknown
-
2018
- 2018-10-14 IL IL262344A patent/IL262344A/en unknown
- 2018-10-19 CO CONC2018/0011195A patent/CO2018011195A2/es unknown
- 2018-10-22 CL CL2018002998A patent/CL2018002998A1/es unknown
- 2018-11-22 ZA ZA2018/07888A patent/ZA201807888B/en unknown
-
2019
- 2019-08-28 US US16/553,670 patent/US20190382494A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2018011195A2 (es) | 2018-10-31 |
| AU2017257505A1 (en) | 2018-12-06 |
| CL2018002998A1 (es) | 2018-12-07 |
| AU2017257505B2 (en) | 2020-05-14 |
| ZA201807888B (en) | 2019-08-28 |
| US10421811B2 (en) | 2019-09-24 |
| AR108317A1 (es) | 2018-08-08 |
| SG11201807474SA (en) | 2018-11-29 |
| KR20180135475A (ko) | 2018-12-20 |
| US20170306025A1 (en) | 2017-10-26 |
| TW201740976A (zh) | 2017-12-01 |
| US20190382494A1 (en) | 2019-12-19 |
| EP3448428A4 (en) | 2019-11-27 |
| CN109069631A (zh) | 2018-12-21 |
| EP3448428A1 (en) | 2019-03-06 |
| RU2018140960A (ru) | 2020-05-26 |
| MA44783A (fr) | 2019-03-06 |
| IL262344A (en) | 2018-11-29 |
| JP2019514889A (ja) | 2019-06-06 |
| MX2018012651A (es) | 2019-01-30 |
| WO2017189433A1 (en) | 2017-11-02 |
| BR112018071287A2 (pt) | 2019-02-19 |
| CA3020893A1 (en) | 2017-11-02 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20201207 |